arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

SCYNEXIS INC

SCYX
$5.30 ▲ +0.08 (+1.63%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
54 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

SCYNEXIS INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $270.1M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -32.4%
FCF / Share $-0.16
Trailing P/E
Price / Book 8.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-21.30M
↓ -295.1%
Operating Margin Operating profit as % of sales
56.4%
↑ +114.2% 3th
FCF / Share Free cash flow per share
$-0.16
↓ -5.3%
Long-Term Debt Long-term obligations
$34.65M
↑ +1.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
29
Financial Health
19
Cash Quality
45

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 54 quarters